We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Issues Guidance on Endpoints for Opioid MATs
Drug sponsors may not have to prove that a proposed medicine-assisted therapy helps addicts completely kick opioids but they will have to detail how well it helps cut dependence to win FDA approval, the agency said in a new draft guidance.
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor